The total number of shares in Biovitrum AB (publ) as per January 29(th), 2010
amounts to 210,041,139 shares, whereof 209,525,554 common shares and 515,585
class C shares[1], corresponding to in total 209,577,112.50 votes. The increase
in the number of shares and votes results from a rights issue of 100,792,632
common shares and an issue in kind of 58,336,606 common shares to certain
shareholders in Swedish Orphan International Holding AB as payment for a total
of around 48 percent of the outstanding shares in Swedish Orphan International
Holding AB.


For further information, please contact:

Göran Arvidson, CFO Biovitrum
Phone: +46 70 633 30 42

Erik Kinnman, EVP Investor Relations Biovitrum
Phone: +46 73 422 15 40
erik.kinnman@biovitrum.com 





About Swedish Orphan Biovitrum
On January 14, 2010, Biovitrum AB (publ) completed the acquisition of Swedish
Orphan International Holding AB and created Swedish Orphan Biovitrum - a leading
company focused on treatment of rare diseases.

Swedish Orphan Biovitrum is a Swedish based specialty pharmaceutical company
with an international market presence. The company is focused on providing and
developing orphan and niche specialist pharmaceuticals to patients with high
medical needs. The portfolio consists of about 60 marketed products and an
emerging late stage clinical development pipe-line within rare diseases. Swedish
Orphan Biovitrum has pro-forma revenues 2009e of about 2 BSEK and approximately
500 employees. The head office is located in Sweden and the share (STO: BVT) is
listed on NASDAQ OMX Stockholm. For more information please visit
www.biovitrum.com <http://www.biovitrum.com/>.



The above information has been made public in accordance with the Securities
Market Act and/or the Financial Instruments Trading Act. The information was
published at 11:30 a.m  CET on January 29(th), 2010.


--------------------------------------------------------------------------------

[1] All class C shares are held by Biovitrum.



[HUG#1378601]





    Press release January 29th in PDF version: http://hugin.info/134557/R/1378601/339061.pdf